Bioinformatics Partnering Terms and Agreements

Published: September 2013
No. of Pages: 1268
   

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.
 
Trends in bioinformatics partnering deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for bioinformatics
 
The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.
 
The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 
This report provides details of the latest bioinformatics agreements announced in the healthcare sectors.
 
Bioinformatics is the application of computer science and information technology to the field of biology and medicine. Bioinformatics deals with algorithms, databases, information systems, web technologies, artificial intelligence, information and computation theory, software engineering, data mining, image processing, modeling, simulation, signal processing, discrete mathematics, control systems, and statistics, for generating new knowledge of biology and medicine.
 
Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing power has been embraced in order to speed up the discovery, evaluation and clinical assessment processes.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
 
This report contains a comprehensive listing of all bioinformatics partnering deals announced since January 2007, including financial terms where available, including over 1700 links to online deal records of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
 
The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
                    
Chapter 3 provides a review of the leading bioinformatics deals since 2007. Deals are listed by headline value, signed by bigpharma, most active big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
 
Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
 
Chapter 6 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 
In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z , deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 
The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2007.
                                                  
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products.
 
Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:
 
• In-depth understanding of bioinformatics deal trends since 2007
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of bioinformatics agreements with numerous real life case studies
•Comprehensive access to over 1700  bioinformatics deals entered into by the world’s biopharma companies
• Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies
• Insight into the terms included in a bioinformatics agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies
 
Report scope
 
Bioinformatics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to bioinformatics trends and structure of deals entered into by leading companies worldwide.
 
Bioinformatics Partnering Terms and Agreements includes:
o Trends in bioinformatics dealmaking in the biopharma industry since 2007
o Analysis of bioinformatics deal structure
o Access to headline, upfront, milestone and royalty data
o Case studies of real-life bioinformatics deals
o Access to over 1700 bioinformatics deal documents
o Access to contract documents where available
o The leading bioinformatics deals by value since 2007
o Most active bioinformatics dealmakers since 2007
o The leading bioinformatics partnering resources In Bioinformatics Partnering Terms and Agreements, the available contracts are listed by:
o Company A-Z
o Headline value
o Stage of development at signing
o Deal component type
o Therapy target
 
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Bioinformatics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 bioinformatics deals. Analyzing actual contract agreements allows assessment of the following:
o What are the precise bioinformatics rights granted or optioned?
o What is actually granted by the agreement to the partner company?
o What exclusivity is granted?
o What is the payment structure for the deal?
o How are sales and payments audited?
o What is the deal term?
o How are the key terms of the agreement defined?
o How are IPRs handled and owned?
o Who is responsible for commercialization?
o Who is responsible for development, supply, and manufacture?
o How is confidentiality and publication managed? o How are disputes to be resolved?
o Under what conditions can the deal be terminated? o What happens when there is a change of ownership?
o What sublicensing and subcontracting provisions have been agreed? o Which boilerplate clauses does the company insist upon?
o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
o Which jurisdiction does the company insist upon for agreement law?
 
Number of pages: The report consists of 1268 pages (including appendices)

Bioinformatics Partnering Terms and Agreements

Table of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in bioinformatics dealmaking
2.1. Introduction
2.2. Bioinformatics partnering over the years
2.3. Big pharma bioinformatics dealmaking activity
2.4. Big Biotech bioinformatics dealmaking activity
2.5. Most active bioinformatics dealmakers
2.6. Bioinformatics partnering by deal type
2.7. Bioinformatics partnering by stage of development
2.8. Bioinformatics partnering by disease type
2.9. Average deal terms for bioinformatics partnering
2.9.1 Bioinformatics partnering headline values
2.9.2 Bioinformatics deal upfront payments
2.9.3 Bioinformatics deal milestone payments
2.9.4 Bioinformatics royalty rates
 
Chapter 3 – Leading bioinformatics deals
3.1. Introduction
3.2. Top bioinformatics deals by value
3.3. Top bioinformatics deals involving big pharma
 
Chapter 4 – Bigpharma bioinformatics deals
4.1. Introduction
4.2. How to use bigpharma bioinformatics partnering deals
4.3. Big pharma bioinformatics partnering company profiles
Abbott
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Galderma
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Lundbeck
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shire
Takeda
Teva
UCB
Valeant
 
Chapter 5 – Bigbiotech bioinformatics deals
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech bioinformatics partnering company profiles
Array Biopharma
Dendreon
Elan
Galapagos
Genmab
Grifols
Ipsen
Novo Nordisk
Onyx Pharmaceuticals
Spectrum Pharmaceuticals
Vertex Pharmaceuticals
 
Chapter 6 – Bioinformatics dealmaking directory with contracts
6.1. Introduction
6.2. By stage of development
Discovery
Formulation
Marketed
Phase III
6.3. By deal type
Asset purchase
Bigpharma outlicensing
Collaborative R&D
Co-market
Contract service
Co-promotion
Development
Distribution
Equity purchase
Licensing
Litigation
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Sub-license
Supply
Termination
6.4. By therapy area
Cardiovascular
Hematology
Hospital care
Infectives
Oncology
 
Chapter 7 – Bioinformatics dealmaking by technology type
Bioinformatics
Software tools
 
Chapter 8 – Partnering resource center
8.1. Online partnering
8.2. Partnering events
8.3. Further reading on dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form – Reports
 
 
Appendices
 
Appendix 1: By company A-Z
Appendix 2: By stage of development
Appendix 3: By deal type
Appendix 4: By therapy area
 
 
List of Figures
 
Figure 1: Bioinformatics partnering since 2007
Figure 2: Big pharma – top 50 – bioinformatics deals 2007 to 2013
Figure 3: Big pharma biomarker deal frequency – 2007 to 2013
Figure 4: Big biotech – top 50 – bioinformatics deals 2007 to 2013
Figure 5: Big biotech biomarker deal frequency – 2007 to 2013
Figure 6: Active bioinformatics dealmaking activity– 2007 to 2013
Figure 4: Bioinformatics partnering by deal type since 2007
Figure 5: Bioinformatics partnering by deal type since 2007
Figure 6: Bioinformatics partnering by disease type since 2007
Figure 10: Bioinformatics deals with a headline value – by stage of development
Figure 11: Bioinformatics deal headline value distribution – discovery stage, US$million
Figure 12: Bioinformatics deal headline value distribution – preclinical stage, US$million
Figure 13: Bioinformatics deal headline value distribution – phase I stage, US$million
Figure 14: Bioinformatics deal headline value distribution – phase II stage, US$million
Figure 15: Bioinformatics deal headline value distribution – phase III stage, US$million
Figure 16: Bioinformatics deal headline value distribution – regulatory stage, US$million
Figure 17: Bioinformatics deal headline value distribution – marketed stage, US$million
Figure 18: Summary median headline value by stage of development, 2007-2013
Figure 19: Bioinformatics deals with upfront payment values – by stage of development
Figure 20: Bioinformatics deal upfront payment distribution – discovery stage, US$million
Figure 21: Bioinformatics deal upfront payment distribution – preclinical stage, US$million
Figure 22: Bioinformatics deal upfront payment distribution – phase I stage, US$million
Figure 23: Bioinformatics deal upfront payment distribution – phase II stage, US$million
Figure 24: Bioinformatics deal upfront payment distribution – phase III stage, US$million
Figure 25: Bioinformatics deal upfront payment distribution – regulatory stage, US$million
Figure 26: Bioinformatics deal upfront payment distribution – phase marketed stage, US$million
Figure 27: Summary median upfront value by stage of development, 2007-2013
Figure 28: Bioinformatics deals with milestone payments – by stage of development
Figure 29: Bioinformatics deal milestone value distribution, US$million – discovery stage
Figure 30: Bioinformatics deal milestone value distribution, US$million – preclinical stage
Figure 31: Bioinformatics deal milestone value distribution, US$million – phase I stage
Figure 32: Bioinformatics deal milestone value distribution, US$million – phase II stage
Figure 33: Bioinformatics deal milestone value distribution, US$million – phase III stage
Figure 34: Bioinformatics deal milestone value distribution, US$million – regulatory stage
Figure 35: Bioinformatics deal milestone value distribution, US$million – marketed stage
Figure 36: Bioinformatics deals with royalty rates- by stage of development
Figure 37: Bioinformatics deal royalty rates value distribution, US$million – discovery stage
Figure 38: Bioinformatics deal royalty rates value distribution, US$million – preclinical stage
Figure 39: Bioinformatics deal royalty rates value distribution, US$million – phase I stage
Figure 40: Bioinformatics deal royalty rates value distribution, US$million – phase II stage
Figure 41: Bioinformatics deal royalty rates value distribution, US$million – phase III stage
Figure 42: Bioinformatics deal royalty rates value distribution, US$million – regulatory stage
Figure 43: Bioinformatics deal royalty rates value distribution, US$million – marketed stage
Figure 44: Summary median milestone value by stage of development, 2007-2013
Figure 45: Top bioinformatics deals by value since 2007
Figure 46: Top bioinformatics deals signed by big pharma value since 2007
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events

Published By: Current Partnering
Product Code: Wildwood Ventures Ltd20


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:

  • Discovery Stage Partnering Terms and Agreements

    The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare com...

  • Vaccine Partnering Terms and Agreements

    The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in vaccine a...

  • Diagnostics Partnering Terms and Agreements

    The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.The report provides a detai...

  • Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

    The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the world’s bioph...

  • Biomarker Partnering Terms and Agreements

    The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in bioma...

  • Companion Diagnostics Partnering Terms & Agreements

    The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access tthe companion diagnostics partnering deals and agreements entered intby the worlds leading healthcare companies....


Why ReportsnReports.com?

  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100